Talk:Peter R. Dolan

This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.

If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page.

Biography

	Biography portal This article is within the scope of WikiProject Biography, a collaborative effort to create, develop and organize Wikipedia's articles about people. All interested editors are invited to join the project and contribute to the discussion. For instructions on how to use this banner, please refer to the documentation.BiographyWikipedia:WikiProject BiographyTemplate:WikiProject Biographybiography articles
	An editor has requested that an image or photograph be added to this article.

Business Start‑class Low‑importance

	Business portal This article is within the scope of WikiProject Business, a collaborative effort to improve the coverage of business articles on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.BusinessWikipedia:WikiProject BusinessTemplate:WikiProject BusinessWikiProject Business articles
Start	This article has been given a rating which conflicts with the project-independent quality rating in the banner shell. Please resolve this conflict if possible.
Low	This article has been rated as Low-importance on the project's importance scale.

United States: Massachusetts / Dartmouth Low‑importance

	United States portal This article is within the scope of WikiProject United States, a collaborative effort to improve the coverage of topics relating to the United States of America on Wikipedia. If you would like to participate, please visit the project page, where you can join the ongoing discussions. Template Usage Articles Requested! Become a Member Project Talk Alerts United StatesWikipedia:WikiProject United StatesTemplate:WikiProject United StatesUnited States articles
Low	This article has been rated as Low-importance on the project's importance scale.
	Massachusetts portal This article is supported by WikiProject Massachusetts (assessed as Low-importance).
	This article is supported by WikiProject New Hampshire - Dartmouth College (assessed as Low-importance).

Neutrality dispute

This article seems biased and looking at the history it appears that all potentially critical comments have been removed by a few users. Peter Dolan was by any measure the worst CEO of any pharmaceutical company in the industry, and his name is associated with the BMS scandals.

A Forbes article gives a totally different view of Dolan that is more in agreement with what everyone in the industry believes: (http://www.forbes.com/2006/09/12/bristol-myers-dolan-sacked-biz-bizhealth_cz_mh_0912bristol.html)

"Almost since Dolan took the helm of Bristol-Myers on May 1, 2001, he has been dogged by criticism. Seen as a sharp, young "golden boy" who at 45 had turned around Bristol's drug and medical device divisions, he was the handpicked successor of former Chief Executive Charles Heimbold.

But very quickly, things started to go wrong. One of his first moves was to buy the drug division of DuPont (nyse: DD - news - people ) for $7.8 billion. Some analysts said he overpaid, and the deal has not yielded big returns. After that, he paid $2 billion for Erbitux, the colon cancer drug from ImClone (nasdaq: IMCL - news - people ). Many analysts said he again overpaid, and an insider trading scandal and a U.S. Food and Drug Administration delay allowed him to negotiate a cheaper deal.

Dolan also survived an accounting scandal relating to "channel stuffing," in which Bristol gave incentives to drug wholesalers to temporarily juice sales. This in effect made the company look healthier than it was, and resulted in the deferred prosecution agreement.

For a moment, it seemed as if Dolan might survive to rebuild his company. Bristol's drug pipeline started to mature, and medicines lsuch as schizophrenia treatment Abilify and AIDS drug Reyataz were hits. Then came the disastrous deal with Apotex, in which that company's chief executive publicly crowed that he had outsmarted Dolan." —Preceding unsigned comment added by Dreamercon (talk • contribs) 03:03, 18 September 2008 (UTC)[reply]

IP, you need to stop removing the tag. This article is a promotional puff piece, not remotely neutral or encyclopedic. TravellingCari 22:00, 29 September 2008 (UTC)[reply]

This is an ad, not a bio

I am in complete agreement with TravellingCari, having worked at BMS during the Dolan years. Dolan took a company that was in serious contention for the title, "Best Pharmaceutical Company" and destroyed the company and the stock value over his tenure. Those of us who trusted the company under Heimbold were rewarded with having our 401k's decreased by half under Dolan; stock options for top performers became jokes because no one believed the stock would ever go back up in value. Why didn't the board, after Dolan being elected "worst CEO in the pharmaceutical industry" by at least one respected financial publication, fire him before he did more damage? That is the real Peter Dolan story: he destroyed the company and financial futures of many of its employees-and that is the story that should appear here, or the entire entry removed. —Preceding unsigned comment added by Dehughes (talk • contribs) 16:50, 31 March 2009 (UTC)[reply]